Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024 [Yahoo! Finance]
Summit Therapeutics Inc. (SMMT)
Last summit therapeutics inc. earnings: 6/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
summitplc.com/investors/investor-centre
Company Research
Source: Yahoo! Finance
Cancer Congress with Ivonescimab Alone or Combined with Chemotherapy Achieving 34% Intracranial Responses; Median Intracranial PFS of 19.3 months in NSCLC Patients with Brain Metastases Board of Directors Strengthened with the Addition of Dr. Mostafa Ronaghi Updated Guidance of Cash Runway for Operations through Q1 2025 MIAMI, May 01, 2024 BUSINESS WIRE )--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024. Operational & Corporate Updates Our operational progress continues with ivonescimab (SMT112), an investigational, potentially first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule: January 2024 marked the one-year anniversary of the close of our Collaboration and License Agreement with Akes
Show less
Read more
Impact Snapshot
Event Time:
SMMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SMMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SMMT alerts
High impacting Summit Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
SMMT
News
- Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $7.00 price target on the stock.MarketBeat
- Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024Business Wire
- Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024Business Wire
- Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of DirectorsBusiness Wire
- Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum [Yahoo! Finance]Yahoo! Finance
SMMT
Earnings
- 5/1/24 - In-Line
SMMT
Sec Filings
- 5/13/24 - Form 8-K
- 5/13/24 - Form 424B5
- 5/1/24 - Form S-8
- SMMT's page on the SEC website